Drug intelligence / Profile preview

BR5402B

Development stage: Unknown
Lead developer: Boryung
Modality: Small Molecules
Administration: Oral

Overview

BR5402B is an investigational drug being developed for the treatment of schizophrenia. It appears to be a formulation of olanzapine with a specific titration schedule being evaluated in clinical trials.

Other names: BR5402B-1BR-5402B-1BR 5402B-1

Targets

HTR2A (Serotonin receptor 5-HT2A)DRD2 (Dopamine D2 Receptor)

Beyond the preview

Go deeper on BR5402B.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BR5402B.

Explore the full profile